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Ca2+ signallingus second messenger which promotes cell responses through transient changes
in intracellular concentrations. The prominent role of Ca2+ in cell physiology is mediated by a whole set of
proteins constituting a Ca2+-signalling toolkit involved in Ca2+-signal generation, deciphering and arrest.
The different Ca2+-signalosomes deliver Ca2+-signals with spatial and temporal dynamics to control the
function of speciﬁc cell types. Among the intracellular proteins involved in Ca2+-signal deciphering,
calmodulin (CaM) plays a pivotal role in controlling Ca2+-homeostasis and downstream Ca2+-based
signalling events. Due to its ubiquitous expression in eukaryotic cells and the variety of proteins it interacts
with, CaM is central in Ca2+-signalling networks. For these reasons, it is expected that disrupting or
modifying CaM interactions with its target proteins will affect Ca2+-homeostasis and cellular responses. The
resulting calcium response will vary depending on which interactions between CaM and target proteins are
altered by the molecules and on the speciﬁc Ca2+-toolkit expressed in a given cell, even in the resting state.
In the present paper, the effect of six classical CaM interactors (W5, W7, W12, W13, bifonazole and
calmidazolium) was studied on Ca2+-signalling in tumor initiating cells isolated from human glioblastoma
(TG1) and tobacco cells (BY-2) using the ﬂuorescent Ca2+-sensitive Indo-1 dye and aequorin, respectively.
Various Ca2+-ﬁngerprints were obtained depending both on the CaM interactor used and the cell type
investigated. These data demonstrate that interaction between the antagonists and CaM results in a
differential inhibition of CaM-dependent proteins involved in Ca2+-signal regulation. In addition, the distinct
Ca2+-ﬁngerprints in tobacco and human tumor initiating glioblastoma cells induced by a given CaM
interactor highlight the speciﬁcity of the Ca2+-signalosome in eukaryotic cells.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionCellular stimulation induces generally a cytosolic calcium signal
that is the result of an exquisite balance between the activity of
proteins involved in calcium entry, calcium exclusion and calcium
buffering. These proteins are produced through the expression of a set
of genes belonging to the calcium toolkit of an organism [1,2]. A given
cell in a given physiological state will express a subset of the calcium
toolkit genes. Consequently, identical external stimuli may induce
different calcium signals in distinct differentiated eukaryotic cells of
the same as well as of other organisms.
For a given stimuli, the observed calcium signal is characterized by
its shape and intensity in time and space. Because these characteristics
are speciﬁc of the stimulus and of the physiological state of the cell,
they constitute a calcium signature of the cell in a speciﬁc context
[3,4]. This calcium signature is shaped by a stringent regulation of thech).
ll rights reserved.cytosolic calcium homeostasis which primarily involvesmodulation of
calcium channels activity by external stimuli but also by feedback
controls of calcium channels, pumps and exchangers by the cytosolic
calcium concentration itself. The free cytosolic calcium concentration
is detected by calcium sensor proteins able to transduce spatial and/or
time modiﬁcations of the cytosolic calcium concentration into
modulation of enzyme activities and/or arrangement of intracellular
structures (modiﬁcation of the cell shape, plasticity of the cytoskeletal
meshwork). More than 200 genes of the human or the plant calcium
toolkit code for proteins endowed with this property. Among these
proteins, CaM is the prototype and is expressed inmost of the cells of a
given organism [5]. The other sensor proteins are generally restricted
to speciﬁc cell types or are expressed in a given physiological context.
CaM exerts a major role both in regulating calcium homeostasis
and intracellular signalling. The fact that CaM has been selected as a
calcium hub along evolution may explain why CaM is ubiquitously
expressed in the eukaryotic cell [6–9].
In order to decipher the role of CaM, a search for CaM interacting
drugs has been underway since the 70's. To address the question of
CaM involvement in a given cellular function, a variety of molecules
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largely used in biological laboratories, mainly in the 80's. Recently, the
use of CaM antagonists resumed due to the renewal of chemical
biology and the fact that CaM could be an interesting therapeutic
target in some types of cancers and in inﬂammatory diseases [10,11].
However, CaM antagonists suffer from two drawbacks, namely the
lack of speciﬁcity that hampers a simple interpretation of inhibitory
data and the chemical diversity of these molecules that makes a
simple structure activity relationship analysis difﬁcult, if not impos-
sible [12,13].
In order to circumvent the non-speciﬁcity of CaM antagonist
effects, twin molecules have been designed: one molecule with high
afﬁnity for CaM and its counterpart with lower afﬁnity. Two such
couples, namely W5/W7 and W12/W13, have been largely used to
investigate CaM functions [14,15].
Moreover, the fact that a large variety of chemical structures may
bind to CaM illustrates the plasticity of this protein, with its ability to
adapt its shape to different molecules [16]. The plasticity of CaM
implies the formation of a large palette of conformations that
recognize different protein domains and small molecules. The co-
crystallisation of CaM with various small molecules exquisitely
illustrates this paradigm.
We reasoned that the differential binding properties of low MW
drugs to CaM would affect the association of CaM with its target
proteins [14] and result in differential biological outcomes.
CaM appears to be a calcium hub in the cell and is involved in the
regulation of the calcium cytoplasmic homeostasis. The induced
calcium signature may be attributable to a differential effect of
antagonists onto the CaM-regulated calcium entry and/or calcium
extrusion mechanisms in the cell [17]. Therefore, a speciﬁc CaM
antagonist might be able to trigger a speciﬁc calcium signal shape
(calcium signature) that will be a ﬁngerprint of part of the expressed
calcium toolkit in a given cell. If this calcium signature is most
speciﬁcally due to a perturbation of CaM dependent regulated
mechanisms, we anticipate a correlation between the CaM antago-
nists binding properties and the observed calcium signature induced
by the same antagonists.
We have addressed the relevance of our working hypothesis by
studying the effects of selected couples of CaM antagonists on the
potential perturbation of the homeostasis of free cytosolic calcium in
animal and plant cell lines.
In this paper, we describe ﬁrstly the CaM binding properties and
mechanisms of three couples of molecules (calmidazolium/bifona-
zole, W5/W7 and W12/W13). Then, we compare the calcium
signatures induced by these molecules in two cell types, a cancer
mammalian cell line (TG1, human cancer initiating cells) and a plant
cell line (tobacco BY-2 cells).
The biophysical-based approach used to compare the binding
mechanism of CaM antagonists to CaM suggests that these drugs are
not functionally equivalent. We show further that CaM is mainly a
regulator of cytoplasmic calcium homeostasis. We hypothesize that
such a central function may explain why CaM is expressed in all
eukaryotic cells and not restricted to speciﬁc cell types. Finally, we
show, that one can use the tool set of CaM antagonists not only to
perturb CaM function but also to ﬁngerprint the expressed calcium
toolkit of a given eukaryotic cell. This ﬁngerprint is a biomarker that
may be used to follow the modiﬁcation of the expression proﬁle of a
calcium toolkit upon proliferation and/or differentiation of the
eukaryotic cell.
2. Experimental section
2.1. Materials
All chemicals were obtained from commercial suppliers and used
without further puriﬁcation. DMSO, KCl, HEPES, calmidazolium andEGTAwere purchased from Sigma.W5 andW7were fromMerck,W12
and W13 were from VWR, bifonazole was from Axxora Platform, Tris
from Aldrich and CaCl2 from Fluka. Ultra pure water (Milli Q
instrument from Millipore Corp. MA, USA) was used for the aqueous
solutions.
The assays were carried out with synthetic CaM (SynCaM), a
hybrid between mammalian and plant CaM [18].
When necessary, Ca2+ was removed from SynCaM using trichlor-
oacetic acid precipitation as described [19].
Fluorescent probe CHPO 199-5-B05 ortho isomer (16B05 ortho)
was selected from the ﬂuorescent polarization screening assay applied
to CaM and characterized biophysically [20].
2.2. Spectroscopic measurements
Steady-state absorption spectra were recorded on a Shimadzu
spectrophotometer to determine the protein and ﬂuorescent probe
16B05 ortho isomer concentrations. Extinction coefﬁcients of 1500
and 88000 M−1.cm−1 were used for SynCaM and the lissamine-
tagged probe, respectively. All spectra were corrected for lamp
intensity variations and background. All the measurements were
carried out at 20 °C.
2.3. Fluorescence polarization (FP) titration of CaM antagonists
FP-titrations were performed using Victor3 apparatus (Perkin–
Elmer Life and Analytical Sciences, Boston, MA) and carried out at
25 °C. Binding assays were conducted in Corning Costar 96-well black
polystyrene ﬂat-bottomed plates (Model 3686; Corning, Acton, MA).
The FP-titrations were performed by adding to each well, succes-
sively, 15 μL of a mixture of SynCaM (2 μM) and the 16B05 ortho
isomer probe (200 nM) in the assay buffer (50 mM HEPES, 150 mM
KCl, 10 μM CaCl2, pH 7.5) and 15 μL of CaM-antagonists, in the same
buffer with ﬁnal concentrations ranging from 0.5 to 500 μM. The plate
was shaken and incubated for 5 min at room temperature. The
polarization degrees (FP) were measured with an excitation
wavelength set at 530 nm (bandwidth 7 nm) and an emission
wavelength set at 610 nm (bandwidth 10 nm). For each plate, FP were
measured versus control wells containing 16B05 ortho isomer probe
bound to CaM and the unbound 16B05 ortho isomer probe alone
(unbound probe).
Probe displacement by different concentrations of CaM antagonists
was monitored by steady-state ﬂuorescence polarization. The equili-
brium binding between a ﬁxed concentration of the ﬂuorescent probe
and its free increasing concentration, as a result of the probe
displacement by CaM-antagonists, was monitored by ﬂuorescence
polarization and equilibrium parameters were determined by non
linear curve ﬁtting. The different models are described in the results
and discussion section.
2.4. Data analysis
The polarization degree is deﬁned by the equation FP=(I//− I⊥)/
(I//+I⊥) where FP is the ﬂuorescence polarization degree, I// and I⊥
are the ﬂuorescence intensities of the vertically (//) and
horizontally (⊥) polarized emission when the sample is excited
with vertically polarized light. For each plate, background correc-
tion was done by subtracting blank parallel and perpendicular
components (means of 8 wells containing only buffer) from the
respective intensities.
The ﬂuorescence polarizationmeasurements were often expressed
in anisotropy because its values can be combined additively.
Anisotropy values (A) were obtained from polarization (P) as follows:
A=
2P
3−P
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ITC measurements were carried out at 25 °C using a VP-ITC
titration calorimeter. All solutions were thoroughly degassed by
magnetic stirring under vacuum before use. The sample cell was
loaded with 1.4 mL of 10 μM or 30 μM SynCaM in 50 mM HEPES,
150 mM KCl, 1 mM CaCl2 buffer pH 7.5 (HEPES/KCl/CaCl2 buffer). The
reference cell contained distilled water. Titrationwas carried out using
a 300-μL syringe ﬁlled with one of the CaM antagonists: 1 mMW12 or
W13 dissolved in HEPES/KCl/CaCl2, 0.5 mMW5,W7 or calmidazolium
dissolved in HEPES/KCl/CaCl2 buffer containing 1% DMSO and
0.25 mM bifonazole in HEPES/KCl/CaCl2 buffer containing 0.5%
DMSO, under continuous stirring at 300 rpm. Injections were started
after baseline stabilization. Each titration experiment consisted of 50
consecutive injections of 3 μL volume and 5.1 s duration for each, with
a 3 min interval between injections. The heat of dilution was
measured by injecting the CaM antagonist into the buffer solution
without protein. The enthalpy change for each injection was
calculated by integrating the area under the peaks of the thermogram
and then subtracting the one of the control titration. Data were
analyzed using MicroCal Origin software and were ﬁtted to obtain
thermodynamic parameters for the CaM-antagonists interactions
with SynCaM binding site(s) using the different models proposed by
the Origin software (see the section results and discussion).
2.6. Plant cell cultures
Tobacco cells (Nicotiana tabacum L. cv BY-2) expressing cytosolic
apo-aequorin were obtained as described previously [21]. Trans-
formed BY-2 cells were grown in suspension under agitation
(130 rpm) at 25 °C in darkness in Linsmaier and Skoog (LS) medium
supplemented with 30 g/L of sucrose and 1 mg/mL of 2,4-
dichlorophenylacetic acid, pH 5.8 [22]. Subculturing was done every
2 weeks with a 2% inoculum of a 14 days old culture.
2.7. Luminescence measurements of [Ca2+]cytosolic in plant cells
Aequorin light emission of tobacco cells was measured using a
digital Sirius luminometer (Berthold Detection Systems, Pforzheim,
Germany). Transformed tobacco BY-2 cell suspensions were collected
during the exponential growth phase, washed twice and resuspended
at a 20% packed cell volume in buffer (2 mM MES KOH, 175 mM
mannitol, 0.5 mM K2SO4, 0.5 mM CaCl2, pH 5.8). In vivo aequorin
reconstitutionwas performed by incubating an appropriate volume of
washed cells with 2.5 μM coelenterazine (Calbiochem, Bad Soden,
Germany) under agitation for at least 3 h in the dark. A variable
amount (50 μL to 100 μL) of reconstituted cells was transferred to a
luminometer cuvette and luminescence was recorded every second
during the experiment. At the end of the experiment, the remaining
reconstituted aequorinwas discharged by adding 300 μL of lysis buffer
(100 mM CaCl2, 10% ethanol (v/v) and 2% Nonidet P-40 (v/v)). The
emitted light intensity was converted into Ca2+ concentrations by
using the calibration formula of Allen et al. [23]:
Ca2 +
h i
= L0=Lmaxð Þ 1=3ð Þ + KTR L0=Lmaxð Þ 1=3ð Þ
h i
−1
h i
= KR− KR L0=Lmaxð Þ 1=3ð Þ
h ih
where [Ca2+] is the calculated Ca2+ concentration, L0 the lumines-
cence intensity (RLU per second), Lmax the total amount of
luminescence present in the entire sample over the course of the
experiment, KR the association constant for the ﬁrst Ca2+ ion to bind,
and KTR the binding constant of the second Ca2+ ion to bind to
aequorin. The luminescence data were determined using KR and KTR
values of 7×106 M−1 and 118 M−1, respectively.2.8. TG1 cells
TG1 cells were kindly provided by Pr Chneiweiss (Ste Anne
Hospital, Paris). The cells were isolated from a form of human
glioblastoma presenting the characteristics of a malignant glioneur-
onal tumor (MGNT) [24]. These cells harbor the features of tumor
initiating cells: long-term self-renewal independent of anchorage in
a deﬁned medium, clonality, reproduction of the original tumor
after intracerebral graft of less than 100 viable cells in immuno-
deﬁcient mice. They are also highly resistant to drugs such as the
alkylating agent temozolomide with less than 40% of cell death up
to 1 mM after 7 days of incubation (Mihalescu-Maingot M. and
Chneiweiss H, unpublished data). Cells were grown in suspension
using T75 ﬂasks and NS34 culture medium essentially made of
DMEM/F12 plus N2, B27 and G5 supplements (Invitrogen). In this
medium, cells grow as neurospheres.
2.9. Measurement of cytosolic calcium in TG1 cells
To measure cytosolic calcium concentration changes, TG1 cells
were loaded with the membrane-permeable Ca2+ ﬂuorescent
probe Indo-1 AM (Fluoprobes) which is cleaved to Indo-1 by
intracellular esterases, allowing intracellular Ca2+ measurements.
The day before the experiment, TG1 neurospheres were mechani-
cally dissociated. Typically, TG1 neurospheres from a 10 mL
culture were harvested, centrifuged at 800 rpm for 10 min,
resuspended in 1 mL of NS34 medium and dissociated by gently
pulling up and down the cell suspension (about 100 times) with
a 1 mL pipette. After addition of 9 mL of NS34 medium, the
dissociated cells were placed back in the incubator overnight. The
next day, the cell culture was centrifuged, the supernatant was
discarded and the cells were washed with PBS. After centrifuga-
tion, the cell pellet was resuspended in 8 mL of HEPES/BSA buffer
(137.5 mM NaCl, 1.25 mM MgCl2, 1.25 mM CaCl2, 6 mM KCl,
5.6 mM glucose, 10 mM HEPES, 0.4 mM NaH2PO4, BSA 1 g/L, pH
7.4) containing 40 μL of a 1 mM Indo-1 AM solution in DMSO (in
the dark). The mixture was transferred in a T75 ﬂask and
incubated for 45 min at 37 °C. Thereafter, the mixture was
centrifuged, the supernatant discarded and the cell pellet washed
twice with PBS and HEPES/BSA buffer and then resuspended in
HEPES/BSA buffer (106 Indo-1 loaded cells per mL). Ca2+
measurements were performed on a Flexstation using 200 μL of
Indo-1 loaded cells per well. Excitation was set at 338 nm and
emission was recorded at 401 and 475 nm, respectively. Baseline
was recorded for 30 s before addition of the compounds. At the
end of the experiment, digitonin was added in each well at a ﬁnal
concentration of 100 μM to give the maximum of the ﬂuorescence
signal.
3. Results and discussion
3.1. Structural characteristics of CaM antagonists
Fig. 1 depicts the structure of the CaM antagonists and the
ﬂuorescent probe used in this work. Most of the CaM antagonists
present a naphtalen, a biphenyl or a tricyclic pharmacophore. In
the present study aiming to further understand CaM antagonists,
we have decided to use two twin molecules derived from
naphtalesulfonamide (W7/W5 and W13/W12), and two diphenyl
derivatives (bifonazole and calmidazolium). The ﬂuorescent probe
that binds to CaM and that will be used in the ﬂuorescence
polarization assay is composed of a naphtalen and a tricyclic
derivative (the lissamine moiety of the molecule). The lissamine
moiety of the molecule is involved in the binding of the probe to
CaM as the ortho derivative has an afﬁnity for CaM 10 times higher
than the para derivative of the probe.
Fig. 1. Structure of W5 (A), W7 (B), W12 (C), W13 (D), Bifonazole (E), calmidazolium (F) and the ﬂuorescent probe used in the anisotropy assay (G). The ﬂuorescent probe interacts
probably with two domains of CaM.
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W13 binding to CaM by microcalorimetry
The binding stoichiometry and afﬁnity of the antagonists for CaM
were determined using isothermal titration calorimetry. ITC curves
were ﬁtted using a model with one binding site or a model with two
independent binding sites. Results are summarized in Table 1 and
Fig. 2. With the exception of W5, all the selected compounds bind to
a high afﬁnity site on CaM (dissociation constants ranging from
1.7 μM to 10 μM). The use of the second model improved the ﬁtting
for W7 and W13 which also bind to a low afﬁnity site (dissociation
constant higher than 100 μM) similar to the afﬁnity site of W5.
Co-crystalisation of W7 with CaM has shown the formation of a
complex with two molecules of W7 for one CaM [16]. Our data seems
to imply that one site presents a higher afﬁnity than the other one.
Binding of calmidazolium, bifonazole, W5 and W12 to CaM is
enthalpy and entropy driven whereas binding of W7 and W13 to the
high afﬁnity sites is only enthalpy driven. Enthalpy changes are
generally associated to ionic interactions either between ligand andTable 1
Antagonists binding parameters calculated from ITC measurements
Compounds K1 (M−1) K2 (M−1) ΔH1 (Cal.mol−1)
ΔS1 (Cal.mol−1 K−1)
ΔH2 (Cal.mol−1)
ΔS2 (Cal.mol−1 K−1)
Calmidazolium 1.34 105 NA −2.6 103 14.9 NA NA
Bifonazole 1.43 105 NA −4.7 103 7.8 NA NA
W5 8.87 103 NA −4.1 103 4.4 NA NA
W12 1.47 105 NA −6.0 1.31 NA NA
W7 2.7 105 3.35 102 −8.18 103 −2.63 −1.18 104 −28
W13 5.77 105 8 103 −9.3 103 −4.8 −3.9 103 4.75
Isothermal titration calorimetry curves have, for calmidazolium, bifonazole, W5 and
W12, been ﬁtted with a one site model. A model with two independent sites has been
used to ﬁt the data for W7 and W13. The association constants for one or two sites (K1
and K2) with the enthalpy and entropy changes associated with the binding for each
site are reported in the table.protein or between protein residues due to conformational modiﬁca-
tions. On the other hand, entropy modiﬁcations are associated to
changes in the number of bound water molecules. It is interesting to
note that besides W5 that exhibits a lower afﬁnity for CaM, all theFig. 2. Isothermal calorimetry titration of SynCam (VU1) with different CaM
antagonists. Enthalpy changes ΔH are measured as a function of mol antagonist
bound per mol CaM. At high concentrations (N=30 μM, calmidazolium is precipitat-
ing). Experimental conditions are described in the experimental section. Symbols
are × for calmidazolium, + for bifonazole, ♦ for W7, - for W13, ∣ for W5 and■ for W12.
Fig. 3. (A) Model of CaM with one binding site for the ﬂuorescent probe (S) and one
binding site for an antagonist (I). k1 and k2 are the site association constants for the
ﬂuorescent probe and the CaM antagonist, respectively. (B) Model of CaM with one
binding site for the ﬂuorescent probe (S) and two binding sites for the antagonist (I). k1
is the site association constant for the ﬂuorescent probe (S), k2 and k3 are the site
association constants for the antagonists (I), c is the coupling factor between the probe
binding site and the antagonist binding site, and d is the coupling factor between the
two CaM antagonist binding sites.
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W12 which is only a weak inhibitor of CaM). The afﬁnity constants
determined by microcalorimetry are similar to the ones reported by
Hidaka et al. [13].
The afﬁnity of W12 for CaM is similar to the one of bifonazole and
of calmidazolium. However, W12 has a weaker potentiality to inhibit
CaM dependent enzymes. Therefore, the difference in activity is
difﬁcult to explain based only on the difference in afﬁnity of the
compound for CaM. Consequently, either the microcalorimetry
approach does not allow encompassing all the steps of the binding
mechanism between a molecule and CaM, or the conformations
induced by the antagonists are different, triggering differential
inhibition of the various target proteins.
Nevertheless, in the naphtalenesulfonamide series, the most
potentially inhibitory drugs (W7 and W13) present negative entropy
upon binding, suggesting a conformational change different from
their twinned molecules (W5 and W12).
3.3. Characterization by ﬂuorescence anisotropy of the binding mode of
CaM antagonists to CaM
To characterize the binding mode of the CaM antagonists, we
used the ﬂuorescent anisotropy assay previously described [20]. A
ﬂuorescent probe that binds to CaM with high afﬁnity in a calcium
dependent manner was competed with the different CaM antago-
nists. The binding of this probe was monitored by ﬂuorescence
anisotropy. This probe binds to two sites on CaM (one high afﬁnity
site with dissociation constant Kd ∼0.16 μM and one low afﬁnity site
with Kd higher than 20 μM) (data not shown). To analyze the
binding of CaM antagonists, a competitive assay was set in which
the concentration of CaM was kept at 1 μM, the concentration of the
probe at 0.1 μM and the concentration of the calmodulin antagonists
varied from 0.5 to 500 μM. Under these conditions, the probe binds
to the high afﬁnity site. Monitoring the ﬂuorescence anisotropy
change of the probe during titration of the CaM-probe complex with
the different CaM antagonists gives information on whether the
antagonists bind to the same site as the ﬂuorescent probe or to a
different site.
The experimental data were ﬁrst analyzed considering model A in
Fig. 3. In this model, the ﬂuorescent probe and the calmodulin
antagonist bind to CaM on two different sites. The model is character-
ized by three parameters: k1 the microscopic binding constant for the
ﬂuorescent probe, k2 the microscopic binding constant for the CaM
antagonist and c, a coupling factor which quantiﬁes the coupling
between the site of the probe and the site of the antagonist. If c equals
0, there is a direct competition between the probe and the antagonist
for CaM binding. If c equals 1, the two sites are independent. Alter-
natively, a value of c higher than 1 indicates a positive cooperativity
between the two sites and lower than 1, a negative cooperativity.
Model (A) is described by the following equations [25]:
vx =
k14x+ c4k14k24x4y
1+ k14x+ k24y+ ck14k24x4y
ð1Þ
where νx is the number of probes per CaM, x =[S], the concentration
of free probe and y =[I] ∼[I]total, the total antagonist concentration.
vx4Ct+ x= St ð2Þ
where Ct is the total concentration of CaM and St the total
concentration of ﬂuorescent probe
Aobs= Af 4
x
St
+ Ab4vx4
Ct
St
ð3Þ
Aobs is the observed anisotropy of the probe, Af is the anisotropy of
the free probe and Ab is the anisotropy of the bound probe assumingthat the quantumyield of the probe does not change upon binding and
that the ﬂuorescence anisotropy of the probe is not affected by the
binding of the antagonist.
To ﬁt data obtained for bifonazole, W5 and W12, we used model A
(1 site for the antagonist). The values of k1 (site association constant
of the probe), Af and Ab are measured in a separate experiment [17].
The value of k2 corresponds to the association constant K1
determined in Table 1.
Model A did not allow to ﬁt data obtained with calmidazolium,W7
and W13. We therefore used model B (Fig. 3) which considers a
second site for the antagonist (I) with a possible coupling mechanism
(represented by the parameter c) between one antagonist binding site
and the probe site and between the two antagonist binding sites
(represented by parameter d).
To represent model B, Eq. (1) has to be replaced by the following
equation:
vx
k14x+ c4k14k24x4y
1+ k14x+ k24y+ k34y+ d4k24k34y2 + ck14k24x4y
ð4Þ
As for W7 and W13, microcalorimetry data have been ﬁtted using
a model with two independent sites, the values of K1 and K2
determined in that experiment (Table 1) were used for k2 and k3
in Eq. (4). k1, the probe association constant is the same as in
model A. The value of the parameter d is 1 as the two sites are
independent.
However, neither model A nor model B allowed to ﬁt the
calmidazolium data. We therefore replaced Eq. (1) by Eq. (5), derived
from a Hill equation (model C).
vx =
k14x4 1+ k34yð Þm 
1+ k24yð Þn + k14x4 1+ k34yð Þm  ð5Þ
with k1 representing the association constant between the
ﬂuorescent probe and CaM (same value as in model A or B), k2
(respectively n) the mean association constant for the binding of
calmidazolium to CaM (respectively the hill coefﬁcient), k3
(respectively m) the binding of calmidazolium to the complex
CaM-ﬂuorescent probe (respectively the hill coefﬁcient of this
complex). Model C implicates four main complexes, namely CaM
alone, CaM with the ﬂuorescent probe, CaM with at least n
molecules of calmidazolium and CaM with one molecule of
ﬂuorescent probe and at least m molecules of calmidazolium.
Moreover, we need to assume that the anisotropy (Ab') of the
ﬂuorescent probe in the last complex (CaM-One ﬂuorescent probe-
m calmidazolium molecules) is intermediary between the aniso-
tropy of the free probe (Af) and the anisotropy of the probe bound
Fig. 4. Displacement of the ﬂuorescent probe 16B5-ortho by CaM antagonists. Experimental conditions are described in the experimental section. Plots have been normalized to
indicate the fractional binding of the probe to its site (ordinate) as a function of CaM antagonist concentrations (abscissa). Calmidazolium/bifonazole (dark blue and light blue
curves), W7/W5 (dark orange and light orange curves) and W13/W12 (dark green and light green curves).
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considerations, Eq. (3) has to be replaced by Eq. (6).
Aobs= Af 4
x
St
+
k14x4 Ab+ AbV4 k34yð Þm 
1+ k24yð Þn + k14x4 1+ k34yð Þm  4
Ct
St
ð6Þ
Fig. 4 shows the displacement plots of the ﬂuorescent probe 16B5
by the different CaM antagonists.
The different experimental plots have been ﬁtted with the
parameters reported in Table 2 using model A for bifonazole, W5
and W12, model B for W7 and W13 and model C for calmidazolium.
The zero or close to zero value for parameter c (W5 and W7)
suggests that the probe and the twinned molecules W7/W5 compete
for the same site of CaM. A value of c close to 0.1 for bifonazole, W12
and W13 suggests that the binding sites of these compounds are not
identical to the probe binding site.
Taking into account the ﬁt of the data for calmidazolium, we
have to assume that at least four calmidazolium molecules bind to
CaM in the absence of probe and that at least six calmidazolium
molecules bind to CaM in the presence of the ﬂuorescent probe with
high positive cooperativity. Although it has been shown that CaM
exhibits four binding sites for triﬂuoperazine (another CaM
antagonist), this has not be shown for calmidazolium. Our observa-
tion suggests possible synergystic effects between different CaM
antagonists.
Based on their binding mechanisms, the CaM antagonists fall into
at least three classes of compounds:
1) the calmidazolium class shows a complex mechanism of competi-
tion with the ﬂuorescent probe,Table 2
Parameters used to ﬁt the experimental data to model A for bifonazole, W5 and W12,
model B for W7 and W13 and model C for calmidazolium
Compounds k1 (μM−1) k2 (μM−1) k3 (μM−1) C n m
Bifonazole 6.25 0.142 NA 0.149 NA NA
W5 6.25 0.009 NA 0 NA NA
W12 6.25 0.147 NA 0.1 NA NA
W7 6.25 0.27 0.0007 0.015 NA NA
W13 6.25 0.578 0.008 0.09 NA NA
Calmidazolium 6.25 0.25 0.076 NA 4 5.52) the W7 and W5 class competes directly with the ﬂuorescent
probe,
3) the W13, W12 and bifonazole class seems to bind to a site that
overlaps with the binding site of the ﬂuorescent probe.
The relative order of potency estimated by the ability of the drugs
(used at a concentration of 125 μM) to displace the ﬂuorescent probe
is as follows: calmidazolium, W7 andW13 (70% and more) bifonazole
and W12 (around 50%) and W5 (less than 25%).
3.4. Calcium signatures induced by CaM antagonists in human cancer
stem cells and in tobacco cells
As calcium signalling plays a central role in proliferation and
differentiation of eukaryotic cells, we have selected these cells to
analyze the calcium signatures induced by the six CaM antagonists
used in our study.
Water insoluble CaM antagonists (calmidazolium, bifonazole and
W5) were solubilized in DMSO so as to maintain their ﬁnal concen-
tration to 1% in the reaction mixture. As shown in Fig. 5B addition of
1% DMSO to TG1 cells did not per se perturb the intracellular calcium
homeostasis.
Among the intracellular CaM antagonists tested, three of them
(W7, W13, calmidazolium) induced a strong calcium signal, one
(bifonazole) a moderate one, whereas W5 andW12 had no visible (or
a very slight) effect even at 300 μM (Fig. 5), or even at 500 μM forW12
(data not shown).
Further analysis of the curves indicates differences in the calcium
signals induced. Indeed, bifonazole and calmidazolium at low
concentration triggered a slight cytoplasmic calcium decrease. This
calcium behavior will be called calcium signature 1.
On the other hand, bifonazole and calmidazolium up to 60 μM
induce a concentration dependent increase of cytoplasmic calcium
starting after a delay of ∼150 s. This will be called calcium signature 2.
It is likely that these effects are not related to a perturbation of CaM as
they are not seen with W7 and W13. At concentrations of
calmidazolium above 60 μM, a concentration independent steady
increase of cytosolic calcium is observed. For TG1 cells, this effect may
be attributed to a detergent effect of calmidazolium.
W7 and W13, but also calmidazolium trigger a transient calcium
wave with a maximum around 120 to 130 s. The parameters of this
Fig. 5. Calcium signal induced in TG1 cells by CaM antagonists at different concentrations. (A) W7, (B) W5, (C) W13, (D) W12, (E) Calmidazolium (Cal) and (F) Bifonazole (BIF). TG1
cells were loaded with Indo-1 as indicated in the experimental section. Indo-1 ﬂuorescence changes at 405 nm and 475 nmwere monitored as a function of time. Ordinate represents
the percent change of the ﬂuorescence intensity ratio (I405/I475) relative to themaximum change of the ratio observedwhen digitoninwas added at t=930 s. Abscissa represents the
time of recording (in seconds). CaM antagonists were injected at t=30 s. Fluorescence was corrected for background. For CaM antagonists solubilized in DMSO (calmidazolium,
bifonazole and W5), the ﬁnal concentration of DMSO in the well is 1%. Experiments have been done at least three times for each CaM antagonist.
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depend on the antagonist and its concentration (Fig. 5). Increasing
antagonist concentration enhances the amplitude of the calciumwave
(up to a certain level) and shortens the time necessary to reach theTable 3
Encoding of the calcium signal induced by the CaM antagonists for TG1 cells
Compounds Calcium signatures
W7 3
W13 3
Calmidazolium 1;2;3
Bifonazole 1;2
For each compound and each concentration used, the calcium signal is considered as the
sum of a subset of three calcium signatures (see text).maximum amplitude. The calcium wave observed corresponds to
calcium signature 3. The concentration independent steady increase
of the basal cytosolic calcium concentration observed for W7 was not
taken into account as it locates within the error interval. Using this
typology, each CaM antagonist-induced calcium signal (CAICS) may
be described as the composition of a subset of those calcium
signatures (see Table 3).
Next, we have addressed the question of whether CaM antagonists
would determine speciﬁc calcium ﬁngerprints in a different eukar-
yotic system, the tobacco BY2 cells. Fig. 6 reports the calcium signals
induced by the six CaM antagonists in these cells.
CaM antagonists also induce cytosolic calcium concentration
changes in tobacco plant cells, although the parameters characterizing
these changes appear to be different from those described for TG1 cells.
Fig. 6. Calcium signal induced in tobacco BY2 cells by CaM antagonists at different concentrations. (A) W7, (B) W5, (C) W13, (D) W12, (E) calmidazolium (Cal) and (F) bifonazole
(BIF). Each curve is the mean of three experiments. Experimental conditions are described in the experimental section. As calmidazolium exhibits only a rapid increase, the
experiment has been performed with an automatic injector in order to follow this early calcium transient (see inset).
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lowering of the cytoplasmic calcium concentrations as in human TG1
cells. Hence, calcium signature 1 deﬁned previously for TG1 cells is
absent.
W7, W13 and bifonazole seem to induce a slight increase in the
basal cytoplasmic calcium concentration similar to calcium signature
2. One striking difference is that calmidazolium does not induce this
signature in plant cells.Table 4
Encoding of the calcium signal induced by the CaM antagonists for plant cells
Compounds Calcium signatures
W7 2,3,4
W13 2,3,4
Calmidazolium 4
Bifonazole 2,3,4
For each compound and each concentration used, the calcium signal is considered as the
sum of a subset of three calcium signatures (see text).A calcium transient around 100 s similar to calcium signature 3 in
TG1 cells is observed for W7, W13, calmidazolium and to a lower
extent for bifonazole.
Speciﬁc to the plant cells is also the rapid transient increase in
response toW7, W13 and with lower amplitude to calmidazolium and
bifonazole. The amplitude of this calcium transient is dependent on
the concentrations of the CaM antagonists (calcium signature 4).
W5 seems to induce a weak transient increase with maximum
amplitude in the 200–300 s range. That is only seen with W5 and is
therefore probably not linked to CaM.
Table 4 summarizes these results on plant cells.
Data presented clearly show that the CaM antagonist-induced
calcium signals (CAICS) are different between the two cell lines:
• Calcium signature 1 (decrease in the basal cytosolic calcium
concentration) is speciﬁc to mammalian cells.
• On the other hand, calcium signature 4 is speciﬁc to the plant cells.
• Two types of calcium signatures are similar between the two
cell lines: a transient calcium wave (calcium signature 3) and
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(calcium signature 2).
• In both cell lines, W7, W13 and calmidazolium seem to lead to
signiﬁcant CAICS. These same compounds were the most
efﬁcient in the competition with the ﬂuorescent probe (Fig. 4).
• Each antagonist has a speciﬁc impact on the characteristics of a
given calcium signature (amplitude and duration of a calcium
wave, level of increase or decrease of the cytosolic calcium
concentration), reﬂecting the complex mode of action of CaM
inside the cell.
4. Conclusion
The thermodynamic characteristics of classical CaM antagonists
binding to CaM have been determined allowing to pinpoint the
speciﬁcity of each CaM antagonist and to illustrate the ability of CaM
to adapt its binding mechanism to the subtle modiﬁcation of a given
pharmacophore.
Collectively, the results described in the present paper also show
for the ﬁrst time that:
a) CaM antagonists induce a calcium signal (CAICS) in human cells as
already shown in plants where they have been used to modulate
calcium-dependent gene expression [26],
b) CAICS are due to a perturbation of CaM or CaM-like proteins as the
counterpart of W7 and W13 (respectively W5 and W12) barely
modify the cytoplasmic calcium concentration either in human or
plant cells,
c) Effects of calmidazolium are probably mediated by CaM as the
calcium signal induced harbors calcium signatures induced by W7
or W13,
d) The induced calcium signal is qualitatively different between
human cells and plant cells, therefore validating the use of CaM
antagonists-induced calcium signals to ﬁngerprint at least part of
the expressed calcium toolkit of a given cell line,
e) For the same cell line, the CaM antagonists-induced calcium signals
(CAICS) are qualitatively and quantitatively different depending on
the antagonist used. This suggests a differential perturbation of
CaM that results in a different induced calcium signal,
f) From the limited set of CaM antagonists, it appears that the
capability of a CaM antagonist to induce a signiﬁcant calcium
signal is not correlated to its afﬁnity to CaM but to its ability to
displace efﬁciently the ﬂuorescent probe used in this study from
CaM. This observation suggests that the ﬂuorescent probe used
may bind to CaM in a manner similar to CaM targets involved in
the generation of the CaM antagonist-induced calcium signal.
These CaM antagonist-induced calcium signals (CAICS) may be
due to induced calcium release from different intracellular stores and
to the inhibition or the activation of calcium pumps or calcium
exchangers directly or indirectly through perturbation of CaM
interactions with different cellular targets. It is worth noting that, in
contrast to animal cells, plant cells express not only a number of
typical CaM isoforms but also a large family of CaM-related proteins
(CML) able to bind calcium ions [27] and which might be targets for
CaM antagonists. The CAICS give insight into the global response of the
cellular calcium homeostasis systemwithout, for the time being, a ﬁne
description of the underlying molecular mechanisms. At ﬁrst, CAICS
may be used as a ﬁngerprint of the general “calcium status” of a cell
allowing to following the change in this “calcium status” upon
modiﬁcation of the cellular physiology. Some studies have reported
these CAICS in porcine aortic endothelium cells using W7 and
calmidazolium [28]. The characteristics of these CAICS appear
different from those described in our study, thus validating our
concept of ﬁngerprint. In this report, the authors suggest an effect of
CaM in regulating the calcium uptake in cytoplasmic stores. In Dic-tyostelium cells, calmidazolium but not W7 induces a transient
cytoplasmic calcium increase [29,30], indicating that in these cells,
the two compounds act differentially on the CaM dependent
regulatory mechanism of calcium homeostasis.
Using different CaM antagonists, it is possible to trigger different
calcium signals and therefore, to induce different cellular events
(either different gene expression proﬁles or modiﬁcation of the
metabolome) [17].
The use of antagonists to decipher cellular pathways or signalling
is always hampered by the lack of speciﬁcity of the chemical
molecules. Nevertheless, the use in this study of twin molecules
bearing great chemical similarity, but showing large differences in
their ability to trigger CAICS (present study), in their ability to
inactivate CaM dependent target enzymes [31] and in their interaction
with CaM (present study) gives some conﬁdence in considering that
small chemical molecules can be found that will inhibit a given
interaction with a given target protein. These molecules are of major
importance in the calcium/CaM ﬁeld as they will allow one more step
in the comprehension of the mode of action of CaM inside cells.
Our next goals are to extend the palette of CaM antagonists able to
induce calcium signals with different shapes and to decipher the
molecular mechanism behind CAICS. To address this last point, wewill
for each ﬁngerprint, determine which calcium signalling proteins are
expressed in a given cell and how their activities are modulated by
CaM and a speciﬁc antagonist.
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